UCB (OTCMKTS:UCBJF) Sees Large Volume Increase – Should You Buy?

UCB SA (OTCMKTS:UCBJF) shares saw strong trading volume on Thursday . 5,872 shares changed hands during mid-day trading, an increase of 551% from the previous session’s volume of 902 shares.The stock last traded at $292.69 and had previously closed at $304.6375.

Analyst Ratings Changes

Several analysts recently weighed in on UCBJF shares. Stephens reissued an “overweight” rating on shares of UCB in a report on Thursday, January 15th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of UCB in a research report on Monday, December 8th. Wolfe Research initiated coverage on UCB in a report on Monday, February 23rd. They set an “outperform” rating for the company. The Goldman Sachs Group reissued a “buy” rating on shares of UCB in a research report on Monday, February 16th. Finally, Barclays reaffirmed an “overweight” rating on shares of UCB in a research report on Tuesday, January 6th. Six research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy”.

UCB Trading Down 3.9%

The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The firm has a fifty day moving average price of $312.11 and a 200-day moving average price of $287.32.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.